Continucare Corp. (AMEX:CNU) continues its run of acquisitions with the purchase Precision Diagnostic Services and SleepEasy Therapeutics.
The Miami-based company purchased the related entities in North Dakota through its Seredor Corp. subsidiary. The deal adds 47 sleep diagnostic centers in eight states, with 44 based in hospitals. It also sells continuous positive airway pressure (PAP) devices.
Continucare Corporation, together with its subsidiaries, provides primary care physician services on an outpatient basis in the United States.
Procera Networks, Inc. (AMEX:PKT) a developer of Evolved Deep Packet Inspection (DPI) solutions providing traffic awareness, control and protection for complex networks, previously announced the release of version 5 of PacketLogic’s™ integration software suite, PacketLogic Subscriber Manager (PSM). This enhanced version 5 offers a significant increase in performance including an upgraded design that enables 50,000 subscribers to be provisioned per second. Version 5 is also the first PSM version with the new administration user interface (GUI) for intuitive configuration, integration setup, creation and modification of service packages, and adjustments to accommodate new network conditions.
Procera Networks, Inc. provides network traffic awareness, analysis, and control solutions for broadband service providers worldwide.
Neuralstem Inc. (AMEX:CUR) recently announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, “Current and Future Clinical Trials and Stem Cell Therapies,” at the World Stem Cell Summit on October 5, in Detroit, MI (http://www.worldstemcellsummit.com/summit-agenda). Dr. Johe is the creator of Neuralstem’s neural stem cell technology. The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.
Neuralstem, Inc., a biopharmaceuticals company, focuses on the development and commercialization of treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs.
Proteonomix, Inc. (PROT.OB) recently reported further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.
Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase.
This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region.
It was further reported that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of PROT proprietary cellular materials for treatment of disease.
Additionally, the agreement calls for XGen, the joint venture, to market and distribute Proteoderm, including the Matrix NC-138 anti-aging products .
Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, http://www.proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products.
For more information about this company please visit http://www.proteonomix.com
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).